Last reviewed · How we verify
Double Antibiotic
Double Antibiotic, marketed by Altamash Institute of Dental Medicine, holds a position in the dental antimicrobial segment with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the lack of immediate generic competition. However, the primary risk is the potential loss of exclusivity post-2028, which could lead to increased competition and revenue erosion.
At a glance
| Generic name | Double Antibiotic |
|---|---|
| Sponsor | Altamash Institute of Dental Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis (NA)
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (PHASE1, PHASE2)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy (NA)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Double Antibiotic CI brief — competitive landscape report
- Double Antibiotic updates RSS · CI watch RSS
- Altamash Institute of Dental Medicine portfolio CI